A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) Families

Familial Cancer

Volumn 10, Issue 3, 2011, Pages 535-543

  Yang, Kathleen Y ^a   Caughey, Aaron B ^b   Little, Sarah E ^c   Cheung, Michael K ^d   Chen, Lee May ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Cost effectiveness analysis; Decision analysis; Hereditary non polyposis colorectal cancer; Lynch Syndrome; Quality of life; Risk reducing surgery

Indexed keywords

ADULT; AGED; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; FEMALE; GYNECOLOGICAL EXAMINATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HYSTERECTOMY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; SALPINGOOOPHORECTOMY;

ADULT; AGED; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COST-BENEFIT ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENITAL NEOPLASMS, FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; TREATMENT OUTCOME; WOMEN;

EID: 80055001120     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-011-9444-z     Document Type: Conference Paper

References (28)

1. M Aarnio R Sankila E Pukkala, et al. 1999 Cancer risk in mutation carriers of DNA-mismatch-repair genes Int J Cancer 81 214 218 10188721 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO;2-L 1:STN:280:DyaK1M3gt1Kjtg%3D%3D (Pubitemid 29144749)
2. MG Dunlop SM Farrington AD Carothers, et al. 1997 Cancer risk associated with germline DNA mismatch repair gene mutations Hum Mol Genet 6 105 110 9002677 10.1093/hmg/6.1.105 1:CAS:528:DyaK2sXlslCmtg%3D%3D (Pubitemid 27033972)
3. HJ Jarvinen JP Mecklin P Sistonen 1995 Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer Gastroenterology 108 1405 1411 7729632 10.1016/0016-5085(95)90688-6 1:STN:280:DyaK2M3ks12ksQ%3D%3D
4. HF Vasen M van Ballegooijen E Buskens, et al. 1998 A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers Cancer 82 1632 1637 9576281 10.1002/(SICI)1097-0142(19980501)82: 9<1632::AID-CNCR6>3.0.CO;2-C 1:STN:280:DyaK1c3jsFyitg%3D%3D (Pubitemid 28208910)
5. W Burke G Petersen P Lynch, et al. 1997 Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium JAMA 277 915 919 9062331 10.1001/jama.277.11.915 1:STN:280:DyaK2s3hs1Snsw%3D%3D (Pubitemid 27123953)
6. KM Schmeler HT Lynch LM Chen, et al. 2006 Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome N Engl J Med 354 261 269 16421367 10.1056/NEJMoa052627 1:CAS:528:DC%2BD28Xls1GqtQ%3D%3D (Pubitemid 43113031)
7. P Watson R Butzow HT Lynch, et al. 2001 The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer Gynecol Oncol 82 223 228 11531271 10.1006/gyno.2001.6279 1:STN:280:DC%2BD3MvovFajsg%3D%3D (Pubitemid 32730595)
8. LM Chen KY Yang SE Little MK Cheung AB Caughey 2007 Gynecologic cancer prevention in lynch syndrome/hereditary nonpolyposis colorectal cancer families Obstet Gynecol 110 18 25 17601891 10.1097/01.AOG.0000267500.27329.85 (Pubitemid 47015695)
9. J Kwon C Sun S Peterson, et al. 2008 Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch Syndrome Cancer 113 2 326 335 18506736 10.1002/cncr.23554
10. NM Lindor GM Petersen DW Hadley, et al. 2006 Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review JAMA 296 1507 1517 17003399 10.1001/jama.296.12.1507 1:CAS:528:DC%2BD28XhtVWmsrbL (Pubitemid 44465515)
11. AA Cowett RM Golub WA Grobman 2006 Cost-effectiveness of dilation and evacuation versus the induction of labor for second-trimester pregnancy termination Am J Obstet Gynecol 194 768 773 16522411 10.1016/j.ajog.2005.09.003 (Pubitemid 43336426)
12. Baker M, Kessler L, Smucker R (1989) Site-specific treatment costs for cancer: an analysis of the medicare continuous history sample file. In: Society AC (ed) Cancer Care and Cost 127-138
13. W McGuire AI Neugut S Arikian J Doyle CM Dezii 1997 Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer J Clin Oncol 15 640 645 9053488 1:STN:280:DyaK2s7nvVOmtw%3D%3D (Pubitemid 27074233)
14. ND Kauff JM Satagopan ME Robson, et al. 2002 Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation N Engl J Med 346 1609 1615 12023992 10.1056/NEJMoa020119 (Pubitemid 34755668)
15. TR Rebbeck HT Lynch SL Neuhausen, et al. 2002 Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations N Engl J Med 346 1616 1622 12023993 10.1056/NEJMoa012158 (Pubitemid 34755669)
16. K Anderson JS Jacobson DF Heitjan, et al. 2006 Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation Ann Int Med 144 397 406 16549852 (Pubitemid 46768161)
17. JS Kwon CC Sun SK Peterson KG White, et al. 2008 Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch Syndrome Cancer 113 326 335 18506736 10.1002/cncr.23554
18. KJ Carter NP Ritchey F Castro, et al. 1998 Treatment of early-stage breast cancer in the elderly: a health-outcome-based approach Med Decis Mak 18 213 219 1:STN:280:DyaK1c3is1Wjtw%3D%3D (Pubitemid 28169591)
19. VR Grann V Sundararajan JS Jacobson, et al. 2000 Decision analysis of tamoxifen for the prevention of invasive breast cancer Cancer J 6 169 178 10882333 1:STN:280:DC%2BD3M%2FgvVaktg%3D%3D (Pubitemid 30469179)
20. BE Hillner JP Hollenberg SG Pauker 1986 Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered Am J Med 80 1115 1127 3728509 10.1016/0002-9343(86)90674- 1 1:STN:280:DyaL283msFKksw%3D%3D
21. MC Weinstein I Schiff 1983 Cost-effectiveness of hormone replacement therapy in the menopause Obstet Gynecol Surv 38 445 455 6310460 10.1097/00006254-198308000-00001 1:STN:280:DyaL3s3pvVKjtg%3D%3D (Pubitemid 15151186)
22. Sun CC (2006) Preferences for cancer prevention strategies (CPS) in women with hereditary nonpolyposis colorectal cancer (HNPCC). J Clin Oncol 24(18S June 20 suppl):1018. Abstract 1018
23. VR Grann JS Jacobson D Thomason, et al. 2002 Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis J Clin Oncol 20 2520 2529 12011131 10.1200/JCO.2002.10.101 (Pubitemid 34525739)
24. VR Grann KS Panageas W Whang, et al. 1998 Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients J Clin Oncol 16 979 985 9508180 1:STN:280:DyaK1c7mslKjtw%3D%3D (Pubitemid 28108730)
25. A Ortega G Dranitsaris J Sturgeon, et al. 1997 Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer Gynecol Oncol 66 454 463 9299261 10.1006/gyno.1997.4786 1:STN:280:DyaK2svks1aqug%3D%3D (Pubitemid 27388139)
26. SK Plevritis AW Kurian BM Sigal, et al. 2006 Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging JAMA 295 2374 2384 16720823 10.1001/jama.295.20.2374 1:CAS:528:DC%2BD28Xlt1WksL8%3D (Pubitemid 43788105)
27. MS Van Roosmalen LC Verhoef PF Stalmeler, et al. 2002 Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oohorectomy J Clin Oncol 20 2092 2100 11956270 10.1200/JCO.2002.08.035 (Pubitemid 34408800)
28. EM Grindedal L Renkonen-Sinisalo H Vasen, et al. 2010 Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds J Med Genet 47 99 102 19635727 10.1136/jmg.2009.068130 1:CAS:528:DC%2BC3cXjvFCrsLc%3D